Overexpression of microRNA-21 in the Serum of Breast Cancer Patients

Author(s): Batool Savari, Sohrab Boozarpour, Maryam Tahmasebi-Birgani*, Hossein Sabouri, Seyed Mohammad Hosseini

Journal Name: MicroRNA

Volume 9 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Breast cancer is the most common cancer diagnosed in women worldwide. So it seems that there's a good chance of recovery if it's detected in its early stages even before the appearances of symptoms. Recent studies have shown that miRNAs play an important role during cancer progression. These transcripts can be tracked in liquid samples to reveal if cancer exists, for earlier treatment. MicroRNA-21 (miR-21) has been shown to be a key regulator of carcinogenesis, and breast tumor is no exception.

Objective: The present study was aimed to track the miR-21 expression level in serum of the breast cancer patients in comparison with that of normal counterparts.

Methods: Comparative real-time polymerase chain reaction was applied to determine the levels of expression of miR-21 in the serum samples of 57 participants from which, 42 were the patients with breast cancer including pre-surgery patients (n = 30) and post-surgery patients (n = 12), and the others were the healthy controls (n = 15).

Results: MiR-21 was significantly over expressed in the serum of breast cancer patients as compared with healthy controls (P = 0.002). A significant decrease was also observed following tumor resection (P < 0.0001). Moreover, it was found that miR-21 overexpression level was significantly associated with tumor grade (P = 0.004).

Conclusion: These findings suggest that miR-21 has the potential to be used as a novel breast cancer biomarker for early detection and prognosis, although further experiments are needed.

Keywords: Antigen, biomarkers, breast cancer, microRNA, MiR-21, serum.

[1]
van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res 2015; 17(1): 21.
[2]
Mangolini A, Ferracin M, Zanzi MV, et al. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res 2015; 3(1): 12.
[3]
Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy. Cancer 2013; 119(6): 1140-8.
[4]
Chen J, Wang X. MicroRNA-21 in breast cancer: Diagnostic and prognostic potential. Clin Transl Oncol 2014; 16(3): 225-33.
[5]
Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016; 17(5): 627.
[6]
Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of Carcinoembryonic Antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008; 13(5): 447.
[7]
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol-Mech 2014; 9: 287-314.
[8]
Ng EK, Wong CL, Ma ES, Kwong A. MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J Oncol 2009; 2009 Article ID 305420
[9]
Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 2010; 38(3): 323-32.
[10]
Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56(11): 1733-41.
[11]
Palmero EI, de Campos SGP, Campos M, et al. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol 2011; 34(3): 363-70.
[12]
Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65(16): 7065-70.
[13]
Chen L, Li Y, Fu Y, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One 2013; 8(1)e54213
[14]
Huang G-L, Zhang X-H, Guo G-L, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21(3): 673-9.
[15]
Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011; 6(9)e24145
[16]
Gharbi S, Mirzadeh F, Khatrei S, et al. Optimizing microRNA quantification in serum samples. J Cell Mol Res 2014; 6(2): 52-6.
[17]
Pereira VB, Zurita-Turk M, Saraiva TDL, et al. DNA vaccines approach: from concepts to applications. WJV 2014; 4(2): 50.
[18]
Hajian-Tilaki K. Receiver Operating Characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med 2013; 4(2): 627.
[19]
Xie Z, Chen G, Zhang X, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 2013; 8(4)e57502
[20]
Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132(7): 1602-12.
[21]
Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 2013; 25(6): 743.
[22]
Han J-G, Jiang Y-D, Zhang C-H, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 2017; 92(2): 55-66.
[23]
Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. Mol Diagn Ther 2015; 19(3): 179-90.
[24]
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57(1): 84-91.
[25]
Leidner RS, Li L, Thompson CL. Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One 2013; 8(3)e57841
[26]
Yadav P, Mirza M, Nandi K, et al. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumour Biol 2016; 37(11): 15275-82.
[27]
Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals. Am J Cancer Res 2015; 5(8): 2484.
[28]
Zhang C, Liu K, Li T, et al. miR-21: A gene of dual regulation in breast cancer. Int J Oncol 2016; 48(1): 161-72.
[29]
Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 2013; 25(6): 743.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 1
Year: 2020
Published on: 17 February, 2020
Page: [58 - 63]
Pages: 6
DOI: 10.2174/2211536608666190318105757
Price: $65

Article Metrics

PDF: 11
HTML: 3